News Updates
Short term improvements only for shoulder revision repair surgery
Source: Medical News Today
Long-term outcomes of revision arthroscopic rotator cuff repair surgery is not as successful as in a first-time surgery, according to researchers from the Orthopaedic Research Institute in Sydney, Australia, who presented their work at the American Orthopaedic Society for Sports Medicine’s (AOSSM) Specialty Day.
Rotator Cuff Repair and Immobilization
Source: Methodist Orthopedics
Shoulder rotator cuff repair aims to suture torn rotator cuff tendons and provide them with the optimal environment to heal and minimize chance of retear. Overall retear rates have decreased over the years, but are still a major concern. Better suture techniques have been thoroughly investigated but there is less attention paid to the rehabilitation protocol. Currently the gold standard for rehabilitation after surgery is to wear an abduction brace and begin physical therapy for passive range of motion within the first few weeks. As surgical techniques have evolved from open surgery to arthroscopic surgery, there are questions as to whether this rehabilitation protocol is ideal. Animal studies have shown that longer periods of immobilization are beneficial to healing after rotator cuff repair.
Collagen for the knee: Gel-like implant invented
Source: Science Daily
Millions of people suffer cartilage damage to the knee every year. Cartilage injuries are not only painful; they can lead to osteoarthritis decades later. In the course of the disease, the protective shock absorbing cartilage that covers the bone within the joint slowly is removed until the bone is finally exposed, typically requiring an artificial joint replacement. A biotechnology company has developed a one-step minimally-invasive surgical procedure for the treatment of cartilage defects: a gel-like implant.
FDA approves Eliquis® (apixaban) to reduce the risk of blood clots following hip or knee replacement surgery
Source: Medical News Today
Bristol-Myers Squibb Company and Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
